A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

Published:2016-01-25 Issue:7 Volume:17 Page:778-784
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Eliades Philip,Miller David M.,Miao Benchun,Kumar Raj,Taylor Michael,Buch Shama,Srinivasa Sreesha P.,Flaherty Keith T.,Tsao Hensin

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/15384047.2016.1139267

Reference25 articles.

1. Distinct Sets of Genetic Alterations in Melanoma

2. Cell cycle control as a promising target in melanoma

3. The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

4. Virtually 100% of melanoma cell lines harbor alterations at the DNA level withinCDKN2A, CDKN2B, or one of their downstream targets

5. Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the potential of chromone scaffold compounds in cancer therapy: targeting key kinase pathways;Medicinal Chemistry Research;2023-04-20

2. Anti-cancer drug molecules targeting cancer cell cycle and proliferation;Control of Cell Cycle & Cell Proliferation;2023

3. Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline;Medicinal Research Reviews;2021-10-04

4. Getting under the skin: The role of CDK4/6 in melanomas;European Journal of Medicinal Chemistry;2020-10

5. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer;Scientific Reports;2019-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3